(Q43086326)

13 November 2017

title

Addition of incretin therapy to metformin in type 2 diabetes (English)

1 reference

13 November 2017

1 reference

1 reference

André J Scheen

1

1 reference

13 November 2017

Régis P Radermecker

series ordinal

2

1 reference

13 November 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

13 November 2017

1 reference

13 November 2017

volume

375

1 reference

13 November 2017

issue

9724

1 reference

13 November 2017

page(s)

1410-1412

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960399-6

7 January 2021

10.1016/S0140-6736(10)60399-6

Identifiers

DOI

1 reference

13 November 2017

1 reference